05:52:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-06-05 X-dag ordinarie utdelning NAVA 0.00 NOK
2024-06-04 Årsstämma
2024-04-30 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-01 Kvartalsrapport 2023-Q3
2023-08-11 Kvartalsrapport 2023-Q2
2023-06-02 X-dag ordinarie utdelning NAVA 0.00 NOK
2023-06-01 Årsstämma
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-01 Kvartalsrapport 2022-Q3
2022-08-12 Kvartalsrapport 2022-Q2
2022-06-03 X-dag ordinarie utdelning NAVA 0.00 NOK
2022-06-02 Årsstämma
2022-05-10 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-06-04 X-dag ordinarie utdelning NAVA 0.00 NOK
2021-06-03 Årsstämma
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-04 X-dag ordinarie utdelning NAVA 0.00 NOK
2020-06-03 Årsstämma
2020-05-14 Kvartalsrapport 2020-Q1
2020-03-11 Extra Bolagsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning NAVA 0.00 NOK
2019-05-28 Årsstämma
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-08 X-dag ordinarie utdelning NAVA 0.00 NOK
2018-06-07 Årsstämma
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-07-28 Kvartalsrapport 2017-Q2
2017-06-07 X-dag ordinarie utdelning NAVA 0.00 NOK
2017-06-06 Årsstämma
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2017-01-13 Extra Bolagsstämma 2017
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-21 X-dag ordinarie utdelning NAVA 0.00 NOK
2016-06-20 Årsstämma
2016-05-11 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-30 Extra Bolagsstämma 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-09 X-dag ordinarie utdelning NAVA 0.00 NOK
2015-06-08 Årsstämma
2015-04-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-10-31 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-10 Årsstämma
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-30 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-23 Årsstämma
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-15 Bokslutskommuniké 2012
2012-02-10 Bokslutskommuniké 2011
2011-10-21 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-05 Kvartalsrapport 2011-Q1
2011-04-14 Årsstämma
2011-02-04 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-26 Kvartalsrapport 2010-Q2
2010-05-05 Kvartalsrapport 2010-Q1
2010-03-25 Årsstämma
2010-02-11 Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Navamedic är ett nordiskt läkemedelsföretag som levererar läkemedel, OTC, medicinska nutritionsprodukter för sällsynta diagnoser samt medicintekniska produkter till sjukhus och apotek inom områden som exempelvis obesitas, kvinnohälsa, urologi, mage/tarm, samt smärta. Navamedic verkar i de nordiska länderna, Baltikum och Benelux men är även representerade i Storbritannien och Grekland. Bolaget etablerades 1999 med säte i Oslo.
2021-11-04 08:00:15
Oslo, 4 November 2021 - Navamedic ASA (OSE: NAVA) grew revenues by 12% in the
third quarter of 2021 compared to the same quarter last year. The company
reported revenues of NOK 63.6 million in the third quarter of 2021 with an
EBITDA of NOK 3.7 million, driven by underlying growth in the portfolio and
Mysimba® in particular. The company reiterates its mid-term ambition of building
a NOK 500 million company through organic growth.

"Our portfolio of specialty pharma and consumer health products continue to grow
with particularly strong performance for the obesity medicine Mysimba, which
grew by 77% in the third quarter. We expect the high demand for Mysimba to
continue going forward, further fueled by the conditional reimbursement in
Finland and roll-out of our successful patient support program, helping obesity
patients across the Nordics to succeed in their treatment," says Kathrine
Gamborg Andreassen, Chief Executive Officer of Navamedic ASA, and continues.

"We are also pleased to see the strong performance of our portfolio of
antibiotics products, displaying solid traction on tenders compared to plan with
new tenders won in several countries."

Revenues in the third quarter of 2021 were NOK 63.6 million (NOK 56.8 million in
the third quarter of 2020). The gross margin was 38.9% (31%), while the EBITDA
was NOK 3.7 million (3.8). In YTD 2021, revenues grew by 21.8% compared to the
same period last year, up from NOK 154.6 million to NOK 188.3 million, while
EBITDA was NOK 10.6 million, up from NOK 2.4 million in the same period last
year. Navamedic will launch products in at least one country in each launch
window going forward. The company targets 20% annual growth from 2021 and
reiterates its mid-term ambition of building a NOK 500 million company through
organic growth with strong gross margins and underlying profitability.

Navamedic is hosting a webcast presentation of the third quarter 2021 financial
results, Thursday 4 November at 08.45 CET. The presentation willbe held at
Sparebank 1 Markets in Olav V's gate 5 in Oslo as well as via webcast on
www.navamedic.com/investors/financial-results under '2021'. Representatives from
Navamedic will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached third quarter 2021 presentation on slide 22.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.